The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 study of QLS1304, a novel, highly potent, and selective dual inhibitor of KAT6A/6B, plus endocrine therapy (ET) in patients (pts) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) breast cancer (BC).
 
Jiong Wu
Consulting or Advisory Role - Lilly
Patents, Royalties, Other Intellectual Property - vascular support dilator of microsurgery
 
Jian Zhang
No Relationships to Disclose
 
Yongli Jin
Employment - QiLu Pharmaceutical
 
Hongying Wei
Employment - QiLu Pharmaceutical
 
Shuang Li
Employment - QiLu Pharmaceutical
 
Xiaoyan Kang
Employment - QiLu Pharmaceutical